Welcome to Mitsubishi Tanabe Pharma America's Independent Research Program Portal
Mitsubishi Tanabe Pharma America, Inc. (MTPA) is committed to supporting independent research initiatives that foster the advancement of scientific and clinical information and improve patient care. The Independent Research Program (IRP) has been created to provide support for Investigator-Initiated clinical research or Health Economics Outcome Independent Research that illustrates the potential to foster knowledge and understanding of MTPA's product RadicavaB. (edaravone). Support from MTPA shall be provided as funding.
MTPA will receive and review applications for independent research conducted in the United States in the therapeutic area of Amyotrophic Lateral Sclerosis (ALS) in the following arenas:
- Clinical research in patients diagnosed with ALS receiving or evaluated for RadicavaB. (edaravone) treatment
- Health Economic Outcome Research proposals in patients diagnosed with ALS, receiving or evaluated for RadicavaB. (edaravone) treatment
- Maximum duration of study must be 2 years with MTPA Independent Research Review Committee interim review at the end of every 12 months.
- MTPA financial support can be requested for permissible research expenses capped at $100,000.00 per application research site/per year (maximum 3 sites) with an additional maximum 25% overhead cost per site allowed, excluding equipment purchase.
- No Research drug-supply (RadicavaB.) nor placebo drug-supply will be made be available through MTPA.
- The final approved protocol must adhere to Good Clinical Practices including all applicable laws, regulations, codes and guidelines and Pharmacovigilance & Product Complaint reporting must adhere to MTPA’s policies and SOPs and applicable laws and regulations.
- The external investigator is responsible for the planning and execution of the study. Any publication, as deemed appropriate by the investigator, is the responsibility of the investigator and the authorship group he/she selects (per ICMJE and GPP3 requirements).
All applications will be reviewed for scientific merit, innovation, clinical impact on patients, and compliance with MTPA policy and requirements. Applications will be approved at MTPA’s sole discretion. At this time, any incomplete application or application in the following areas will not be considered for review:
- Pre-clinical research
- Clinical research already being planned or sponsored by MTPA
- Continuing Medical Education (CME) or other educational activities
- Event sponsorship
- Research supported by patient or advocacy organizations
MTPA’s Independent Research Applicants are required to comply with all applicable laws, regulations, rules, and industry codes related to clinical and/or non-clinical research.
If you already have an account, please enter your login details to the left.B If you’ve forgotten your login details, please click the “Forgot Password?” link.B For first-time users, please use the “Register for Access” link on the left.
Applications are reviewed on a bi-annual basis. The deadline for submission for this application period is Friday, March 6th, 2021.
Once an application is approved, the Investigator will be notified via email within six (6) weeks following the submission deadline.
NOTE: All Proposals must be submitted via the MTPA online IRP application portal. Hard copies will not be accepted.
After March 6th, 2021, new applications will not be accepted. We will update this web page once the new submission period is open.
The information and/or requirements of the IRP are subject to change at any time at MTPA’s sole discretion. MTPA has no obligation to approve applications received.
To contact the Mitsubishi Tanabe Pharma America team:
For Technical Support, please contact SteepRock Client Services:
Phone: +1 718-576-1406 (M-F 8am - 6pm US ET)